{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:02:56Z","timestamp":1787778176577,"version":"build-2784847793"},"reference-count":108,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201400008C"],"award-info":[{"award-number":["HHSN272201400008C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201500033C"],"award-info":[{"award-number":["HHSO100201500033C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["91715372"],"award-info":[{"award-number":["91715372"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Influenza A viruses can infect a wide range of hosts, creating opportunities for zoonotic transmission, i.e., transmission from animals to humans, and placing the human population at constant risk of potential pandemics. In the last hundred years, four influenza A virus pandemics have had a devastating effect, especially the 1918 influenza pandemic that took the lives of at least 40 million people. There is a constant risk that currently circulating avian influenza A viruses (e.g., H5N1, H7N9) will cause a new pandemic. Vaccines are the cornerstone in preparing for and combating potential pandemics. Despite exceptional advances in the design and development of (pre-)pandemic vaccines, there are still serious challenges to overcome, mainly caused by intrinsic characteristics of influenza A viruses: Rapid evolution and a broad host range combined with maintenance in animal reservoirs, making it near impossible to predict the nature and source of the next pandemic virus. Here, recent advances in the development of vaccination strategies to prepare against a pandemic virus coming from the avian reservoir will be discussed. Furthermore, remaining challenges will be addressed, setting the agenda for future research in the development of new vaccination strategies against potentially pandemic influenza A viruses.<\/jats:p>","DOI":"10.3390\/vaccines6030046","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T08:28:47Z","timestamp":1532507327000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Avian Influenza A Virus Pandemic Preparedness and Vaccine Development"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-0127","authenticated-orcid":false,"given":"Rory D.","family":"De Vries","sequence":"first","affiliation":[{"name":"Department of Viroscience, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-8903","authenticated-orcid":false,"given":"Sander","family":"Herfst","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, P.O. Box 2040, 3000CA Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.onehlt.2015.03.001","article-title":"One health, multiple challenges: The inter-species transmission of influenza a virus","volume":"1","author":"Short","year":"2015","journal-title":"One Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1073\/pnas.1116200109","article-title":"A distinct lineage of influenza a virus from bats","volume":"109","author":"Tong","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3201\/eid1209.05-0979","article-title":"1918 influenza: The mother of all pandemics","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0042-6822(78)90153-8","article-title":"On the origin of the human influenza virus subtypes H2N2 and H3N2","volume":"87","author":"Scholtissek","year":"1978","journal-title":"Virology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature08157","article-title":"Emergence and pandemic potential of swine-origin H1N1 influenza virus","volume":"459","author":"Neumann","year":"2009","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/PL00000657","article-title":"Avian influenza viruses infecting humans","volume":"57","author":"Subbarao","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/fvl.14.30","article-title":"Avian influenza a viruses: From zoonosis to pandemic","volume":"9","author":"Richard","year":"2014","journal-title":"Future Virol."},{"key":"ref_8","unstructured":"WHO (2018, July 17). Cumulative Number of Confirmed Human Cases for Avian Influenza a(H5N1) Reported to WHO, 2003\u20132018. Available online: http:\/\/www.who.int\/influenza\/human_animal_interface\/2018_03_02_tableH5N1.pdf?ua=1."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"WHO\/OIE\/FAO H5N1 Evolution Working Group (2008). Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg. Infect. Dis., 14, e1.","DOI":"10.3201\/eid1407.071681"},{"key":"ref_10","unstructured":"WHO (2018, July 17). Antigenic and Genetic Characteristics of Zoonotic Influenza Viruses and Candidate Vaccine Viruses Developed for Potential Use in Human Vaccines. Available online: http:\/\/www.who.int\/influenza\/vaccines\/virus\/characteristics_virus_vaccines\/en\/."},{"key":"ref_11","unstructured":"WHO (2018, July 17). Avian Influenza Weekly Update Number 631. Available online: http:\/\/www.wpro.who.int\/emerging_diseases\/ai_weekly_631_wpro_20180406.pdf."},{"key":"ref_12","unstructured":"FAO (2018, July 17). H7N9 Situation Update. Available online: http:\/\/www.fao.org\/ag\/againfo\/programmes\/en\/empres\/H7N9\/situation_update.html."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00301-18","DOI":"10.1128\/JVI.00301-18","article-title":"New threats of H7N9 influenza virus: The spread and evolution of highly and low pathogenic variants with high genomic diversity in wave five","volume":"92","author":"Quan","year":"2018","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jinf.2017.04.001","article-title":"Human infections with recently-emerging highly pathogenic h7n9 avian influenza virus in china","volume":"75","author":"Zhang","year":"2017","journal-title":"J. Infect."},{"key":"ref_15","unstructured":"WHO (2018, July 17). Antigenic and Genetic Characteristics of Zoonotic Influenza Viruses and Development of Candidate Vaccine Viruses for Pandemic Preparedness. Available online: http:\/\/www.who.int\/influenza\/vaccines\/virus\/201703_zoonotic_vaccinevirusupdate.pdf?ua=1."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, L., Zhu, W., Li, X., Chen, M., Wu, J., Yu, P., Qi, S., Huang, Y., Shi, W., and Dong, J. (2017). Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in mainland china. J. Virol., 91.","DOI":"10.1128\/JVI.01277-17"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cell.2014.02.040","article-title":"Identification, characterization, and natural selection of mutations driving airborne transmission of A\/H5N1 virus","volume":"157","author":"Linster","year":"2014","journal-title":"Cell"},{"key":"ref_20","unstructured":"WHO (2018, July 17). Summary of Status of Development and Availability of Avian Influenza A(H7N9) Candidate Vaccine Viruses and Potency Testing Reagents. Available online: http:\/\/www.who.int\/influenza\/vaccines\/virus\/candidates_reagents\/summary_a_h7n9_cvv_20180305.pdf?ua=1."},{"key":"ref_21","unstructured":"WHO (2018, July 17). Sage Working Group on Influenza Vaccines and Immunizations Influenza A(H5N1) Vaccine Stockpile and Inter-Pandemic Vaccine Use. Available online: http:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/november\/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"c7297","DOI":"10.1136\/bmj.c7297","article-title":"Effectiveness of AS03 adjuvanted pandemic h1n1 vaccine: Case-control evaluation based on sentinel surveillance system in canada, autumn 2009","volume":"342","author":"Skowronski","year":"2011","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.vaccine.2009.01.116","article-title":"A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine","volume":"27","author":"Cox","year":"2009","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: A randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.vaccine.2009.03.082","article-title":"A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults","volume":"27","author":"Talaat","year":"2009","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(03)15014-3","article-title":"Safety and antigenicity of whole virus and subunit influenza A\/Hong Kong\/1073\/99 (H9N2) vaccine in healthy adults: Phase I randomised trial","volume":"362","author":"Stephenson","year":"2003","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","article-title":"Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza","volume":"357","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/428948","article-title":"Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: A potential priming strategy","volume":"191","author":"Stephenson","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Couch, R.B., Decker, W.K., Utama, B., Atmar, R.L., Nino, D., Feng, J.Q., Halpert, M.M., and Air, G.M. (2012). Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050830"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.virol.2016.02.024","article-title":"A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets","volume":"492","author":"Liu","year":"2016","journal-title":"Virology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: Shifting to better vaccines","volume":"34","author":"Tsvetnitsky","year":"2016","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Baras, B., Stittelaar, K.J., Simon, J.H., Thoolen, R.J., Mossman, S.P., Pistoor, F.H., van Amerongen, G., Wettendorff, M.A., Hanon, E., and Osterhaus, A.D. (2008). Cross-Protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001401"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/505225","article-title":"Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge","volume":"194","author":"Govorkova","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1086\/507709","article-title":"Cross-protectiveness and immunogenicity of influenza A\/Duck\/Singapore\/3\/97(H5) vaccines against infection with A\/Vietnam\/1203\/04(H5N1) virus in ferrets","volume":"194","author":"Lipatov","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2016.08.010","article-title":"Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus","volume":"498","author":"Park","year":"2016","journal-title":"Virology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1016\/j.vaccine.2009.04.050","article-title":"Single- and multiple-clade influenza A H5n1 vaccines induce cross protection in ferrets","volume":"27","author":"Forrest","year":"2009","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Rao, S., Kong, W.P., Wei, C.J., Yang, Z.Y., Nason, M., Styles, D., DeTolla, L.J., Panda, A., Sorrell, E.M., and Song, H. (2008). Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS ONE, 3.","DOI":"10.1371\/annotation\/b8b66a84-4919-4a3e-ba3e-bb11f3853755"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11822","DOI":"10.1128\/JVI.00891-10","article-title":"Neutralizing epitopes of influenza virus hemagglutinin: Target for the development of a universal vaccine against H5N1 lineages","volume":"84","author":"Prabakaran","year":"2010","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2017.05.010","article-title":"Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets","volume":"508","author":"Sun","year":"2017","journal-title":"Virology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1093\/infdis\/jix001","article-title":"Cross-reactive antibody responses to novel H5Nx influenza viruses following homologous and heterologous prime-boost vaccination with a prepandemic stockpiled A(H5N1) vaccine in humans","volume":"216","author":"Levine","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2009.01.040","article-title":"Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1750-2659.2012.00423.x","article-title":"Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model","volume":"7","author":"Ducatez","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1128\/JVI.00241-09","article-title":"Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization","volume":"83","author":"Middleton","year":"2009","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1086\/590916","article-title":"Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A\/Vietnam\/1203\/2004 (H5N1) vaccine after priming with an antigenic variant","volume":"198","author":"Goji","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1256427","article-title":"Antibody landscapes after influenza virus infection or vaccination","volume":"346","author":"Fonville","year":"2014","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1073\/pnas.1012457108","article-title":"Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development","volume":"108","author":"Ducatez","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1016\/j.vaccine.2007.01.063","article-title":"Immunogenicity of novel consensus-based DNA vaccines against avian influenza","volume":"25","author":"Laddy","year":"2007","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1128\/JVI.02335-08","article-title":"Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus","volume":"83","author":"Laddy","year":"2009","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Laddy, D.J., Yan, J., Kutzler, M., Kobasa, D., Kobinger, G.P., Khan, A.S., Greenhouse, J., Sardesai, N.Y., Draghia-Akli, R., and Weiner, D.B. (2008). Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002517"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.vaccine.2011.01.100","article-title":"A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets","volume":"29","author":"Giles","year":"2011","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/21645515.2015.1012013","article-title":"Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades","volume":"11","author":"Crevar","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Webby, R.J., and Weaver, E.A. (2015). Centralized consensus hemagglutinin genes induce protective immunity against H1, H3 and H5 influenza viruses. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140702"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e01070-14","DOI":"10.1128\/mBio.01070-14","article-title":"Antigenic variation of clade 2.1 H5N1 virus is determined by a few amino acid substitutions immediately adjacent to the receptor binding site","volume":"5","author":"Koel","year":"2014","journal-title":"MBio"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11735","DOI":"10.1128\/JVI.01084-12","article-title":"Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin","volume":"86","author":"Smit","year":"2012","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/v6031294","article-title":"Playing hide and seek: How glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection","volume":"6","author":"Tate","year":"2014","journal-title":"Viruses"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"18137","DOI":"10.1073\/pnas.0909696106","article-title":"Glycans on influenza hemagglutinin affect receptor binding and immune response","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/JVI.02608-13","article-title":"Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain","volume":"88","author":"Eggink","year":"2014","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lin, S.C., Liu, W.C., Jan, J.T., and Wu, S.C. (2014). Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092822"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza a viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4049\/jimmunol.1201060","article-title":"Toward animal cell culture-based influenza vaccine design: Viral hemagglutinin N-glycosylation markedly impacts immunogenicity","volume":"190","author":"Hutter","year":"2013","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1128\/JVI.00221-10","article-title":"Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A\/Vietnam\/1203\/2004 vaccine virus in ferrets","volume":"84","author":"Wang","year":"2010","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.virol.2014.07.004","article-title":"Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines","volume":"464\u2013465","author":"Sun","year":"2014","journal-title":"Virology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12915","DOI":"10.1073\/pnas.0506416102","article-title":"Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines","volume":"102","author":"Hoffmann","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Burke, D.F., and Smith, D.J. (2014). A recommended numbering scheme for influenza A HA subtypes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112302"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Krenn, B.M., Egorov, A., Romanovskaya-Romanko, E., Wolschek, M., Nakowitsch, S., Ruthsatz, T., Kiefmann, B., Morokutti, A., Humer, J., and Geiler, J. (2011). Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018577"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.vaccine.2010.12.120","article-title":"Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain","volume":"29","author":"Farnsworth","year":"2011","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1126\/science.1244730","article-title":"Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution","volume":"342","author":"Koel","year":"2013","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.09.6","article-title":"Universal M2 ectodomain-based influenza A vaccines: Preclinical and clinical developments","volume":"8","author":"Schotsaert","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Marcelin, G., DuBois, R., Rubrum, A., Russell, C.J., McElhaney, J.E., and Webby, R.J. (2011). A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026335"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"Wohlbold","year":"2015","journal-title":"MBio"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4049\/jimmunol.0902147","article-title":"Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection","volume":"186","author":"Descamps","year":"2011","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DiLillo","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/rmv.1713","article-title":"Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines","volume":"22","author":"Marcelin","year":"2012","journal-title":"Rev. Med. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.vaccine.2014.11.054","article-title":"Virus-specific T cells as correlate of (cross-)protective immunity against influenza","volume":"33","author":"Altenburg","year":"2015","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1099\/vir.0.048652-0","article-title":"Human T-cells directed to seasonal influenza a virus cross-react with 2009 pandemic influenza a (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses","volume":"94","author":"Hillaire","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1128\/JVI.02694-07","article-title":"Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza a virus","volume":"82","author":"Kreijtz","year":"2008","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/JVI.02843-13","article-title":"Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus","volume":"88","author":"Kreijtz","year":"2014","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"11756","DOI":"10.1128\/JVI.01460-06","article-title":"Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines","volume":"80","author":"He","year":"2006","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2009.05.099","article-title":"Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults","volume":"27","author":"Karron","year":"2009","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(17)30240-2","article-title":"Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A\/17\/turkey\/Turkey\/05\/133 H5N2 and its priming effects for potential pre-pandemic use: A randomised, double-blind, placebo-controlled trial","volume":"17","author":"Pitisuttithum","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e01487-15","DOI":"10.1128\/mBio.01487-15","article-title":"Nonreplicating influenza a virus vaccines confer broad protection against lethal challenge","volume":"6","author":"Baz","year":"2015","journal-title":"MBio"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Suguitan, A.L., McAuliffe, J., Mills, K.L., Jin, H., Duke, G., Lu, B., Luke, C.J., Murphy, B., Swayne, D.E., and Kemble, G. (2006). Live, attenuated influenza A H5n1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030360"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"Talaat","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fimmu.2015.00287","article-title":"Boosted influenza-specific T cell responses after H5N1 pandemic live attenuated influenza virus vaccination","volume":"6","author":"Peng","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virusres.2015.01.007","article-title":"H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus","volume":"200","author":"Ren","year":"2015","journal-title":"Virus Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.vaccine.2010.01.029","article-title":"Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin","volume":"28","author":"Smith","year":"2010","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0091-7435(74)90066-8","article-title":"Smallpox vaccination and its consequences: First experiences with the highly attenuated smallpox vaccine \u201cMVA\u201d","volume":"3","author":"Stickl","year":"1974","journal-title":"Prev. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"Rimmelzwaan","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kreijtz, J.H., Suezer, Y., de Mutsert, G., van Amerongen, G., Schwantes, A., van den Brand, J.M., Fouchier, R.A., Lower, J., Osterhaus, A.D., and Sutter, G. (2009). MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A\/H5N1 viruses at low doses and after single immunization. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007790"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/517614","article-title":"Recombinant modified vaccinia virus ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1","volume":"195","author":"Kreijtz","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Hessel, A., Schwendinger, M., Holzer, G.W., Orlinger, K.K., Coulibaly, S., Savidis-Dacho, H., Zips, M.L., Crowe, B.A., Kreil, T.R., and Ehrlich, H.J. (2011). Vectors based on modified vaccinia ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016247"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1086\/595984","article-title":"Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques","volume":"199","author":"Kreijtz","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Xiao, H., Liu, L., Zhu, Q., Tan, Z., Yu, W., Tang, X., Zhan, D., Du, Y., Wang, H., and Liu, D. (2013). A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083274"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5n1 vaccine: A randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3201\/eid2106.150021","article-title":"Induction of influenza (H5N8) antibodies by modified vaccinia virus ankara H5N1 vaccine","volume":"21","author":"Bestebroer","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/infdis\/jiu528","article-title":"A single immunization with modified vaccinia virus ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model","volume":"211","author":"Kreijtz","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"13418","DOI":"10.1128\/JVI.01219-14","article-title":"Modified vaccinia virus ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques","volume":"88","author":"Florek","year":"2014","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.0803467","article-title":"Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice","volume":"182","author":"Poon","year":"2009","journal-title":"J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"13300","DOI":"10.1128\/JVI.01532-14","article-title":"Broad protection against avian influenza virus by using a modified vaccinia ankara virus expressing a mosaic hemagglutinin gene","volume":"88","author":"Kamlangdee","year":"2014","journal-title":"J. Virol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/oxfordjournals.bmb.a071545","article-title":"Determinants of immunity to influenza infection in man","volume":"35","author":"Potter","year":"1979","journal-title":"Br. Med. Bull."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1586\/14760584.2014.922416","article-title":"Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms","volume":"13","author":"Luke","year":"2014","journal-title":"Expert Rev. Vaccines"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/3\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:14:09Z","timestamp":1760195649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/3\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":108,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["vaccines6030046"],"URL":"https:\/\/doi.org\/10.3390\/vaccines6030046","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,25]]}}}